Daniel Anton de Boer net worth and biography

Daniel de Boer Biography and Net Worth

Founding CEO of ProQR Therapeutics

Daniel is the Founder and Chief Executive Officer of ProQR Therapeutics and has served in this role since the company’s incorporation in 2012. He is also an executive director on the ProQR Board of Directors. A serial entrepreneur and passionate advocate for rare disease patients, Daniel founded ProQR after one of his children was diagnosed with a rare genetic disorder, with the objective to develop RNA therapies for rare diseases.

Prior to founding ProQR, Daniel was the founder and Chief Executive Officer of several technology companies. In his capacity as ProQR’s CEO, he also serves on the Board of Directors of the Biotechnology Innovation Organization (BIO), the leading global association representing the biotechnology industry. He also serves on the Board of the Termeer Institute, a nonprofit organization focused on developing the next generation of leaders in biopharma.

What is Daniel Anton de Boer's net worth?: The estimated net worth of Daniel Anton de Boer is at least $519 thousand as of July 9th, 2026. Mr. de Boer owns 300,000 shares of ProQR Therapeutics stock worth more than $519,000 as of July 28th. This net worth evaluation does not reflect any other investments that Mr. de Boer may own. Learn More about Daniel Anton de Boer's net worth.
How do I contact Daniel Anton de Boer?: The corporate mailing address for Mr. de Boer and other ProQR Therapeutics executives is Zernikedreef 9, Leiden P7, 2333 CK. ProQR Therapeutics can also be reached via phone at (188) 166-7000 and via email at [email protected]. Learn More on Daniel Anton de Boer's contact information.
Has Daniel Anton de Boer been buying or selling shares of ProQR Therapeutics?: Over the course of the past ninety days, Daniel Anton de Boer has bought $499,500.00 of ProQR Therapeutics stock. Most recently, on Thursday, July 9th, Boer Daniel Anton De bought 150,000 shares of ProQR Therapeutics stock. The stock was acquired at an average cost of $1.74 per share, with a total value of $261,000.00. Following the completion of the transaction, the chief executive officer now directly owns 300,000 shares of the company's stock, valued at $522,000. Learn More on Daniel Anton de Boer's trading history.
Who are ProQR Therapeutics' active insiders?: ProQR Therapeutics' insider roster includes Daniel de Boer (Founding CEO), and Bart Filius (Director). Learn More on ProQR Therapeutics' active insiders.
Are insiders buying or selling shares of ProQR Therapeutics?: During the last year, ProQR Therapeutics insiders bought shares 3 times. They purchased a total of 450,000 shares worth more than $730,500.00. The most recent insider tranaction occured on July, 9th when CEO Boer Daniel Anton De bought 150,000 shares worth more than $261,000.00. Insiders at ProQR Therapeutics own 8.4% of the company. Learn More about insider trades at ProQR Therapeutics.
Information on this page was last updated on 7/9/2026.

Daniel Anton de Boer Insider Trading History at ProQR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/9/2026	Buy	150,000	$1.74	$261,000.00	300,000
7/7/2026	Buy	150,000	$1.59	$238,500.00	150,000

Daniel Anton de Boer Buying and Selling Activity at ProQR Therapeutics

ProQR Therapeutics Company Overview

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Today's Range

Now: $1.71

$1.66

$1.73

50 Day Range

MA: $1.65

$1.41

$1.89

2 Week Range

Now: $1.71

$1.33

$3.10

Volume

49,421 shs

Average Volume

712,494 shs

Market Capitalization

$179.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04